ArticleFrontiers in genetics2025
Expression and clinical significance of FANCI gene in pan-cancer: a comprehensive analysis based on multi-omics data.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- FANCI promotes esophageal squamous cell carcinoma progression and cell cycle regulation and interacts with FANCD2.Journal of gastrointestinal oncology · 2026Article
- Functional analysis of a splicing variant of the DOCK8 gene in a patient with breast cancer (Buryat ethnicity).Asian Pacific journal of cancer prevention : APJCP · 2026Article
- FANCI: from genome guardian to translational therapeutic target.Frontiers in oncology · 2026Review
- Potential role of Fanconi anemia pathway in the pathogenesis of endometrial cancer (Review).Molecular medicine reports · 2025Review
- Editorial: Screening and discovering novel biological biomarkers by omic-data to revolutionize tumor management.Frontiers in genetics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The FANCI gene, an essential element of the Fanconi anemia pathway, has been associated with a variety of cancer types. This investigation seeks to clarify the expression profiles, prognostic relevance, and diagnostic capabilities of FANCI across multiple malignancies, along with its links to immune cell infiltration, genetic alterations, protein-protein interactions, and functional roles. Methods: By utilizing data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases, we conducted a comprehensive analysis of FANCI mRNA expression using R software and visualized the results with the ggplot2 package. Prognostic and diagnostic evaluations were conducted using Xiantao tools to produce survival and receiver operating characteristic (ROC) curves. The examination of genetic variation was facilitated through cBioPortal, while DNA methylation and mRNA modifications were analyzed utilizing UALCAN and SangerBox 3.0. Correlations with immune responses were assessed via the EPIC platform and SangerBox 3.0. Additionally, we constructed protein-protein interaction networks employing the STRING database and Cytoscape software. Functional enrichment analyses encompassed Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA). The CancerSEA database was also utilized for single-cell level investigation of FANCI's association with the functional states of cancer. Results: Our findings reveal that FANCI is significantly upregulated in the majority of tumor types when compared to normal tissues, with increased protein levels observed in several cancers, including colorectal adenocarcinoma (COAD) and pancreatic adenocarcinoma (PAAD). Elevated FANCI expression is associated with unfavorable prognoses in cancers such as adrenocortical carcinoma (ACC) and liver hepatocellular carcinoma (LIHC). Methylation assessments demonstrated a robust inverse correlation between FANCI promoter methylation and its expression in LIHC. Moreover, FANCI expression was found to be connected to immune cell infiltration and tumor mutation burden in select cancers. Discussion: In summary, FANCI presents as a promising biomarker for cancer prognosis and diagnosis, with potential implications for therapeutic interventions. Subsequent investigations should concentrate on elucidating the mechanistic functions of FANCI in cancer development and assessing its viability as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.